This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Razuprotafib
- DrugBank Accession Number
- DB16353
- Background
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.1,2 In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Razuprotafib (DB16353)
- Weight
- Average: 586.7
Monoisotopic: 586.101448095 - Chemical Formula
- C26H26N4O6S3
- Synonyms
- Razuprotafib
- External IDs
- AKB-9778
- WHO 10271
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Razuprotafib inhibits VE-PTP (a negative regulator of Tie2 in diseased blood vessels) by binding and inhibiting the intracellular catalytic domain of VE-PTP that inactivates Tie2.1 This in turn allows razuprotafib to restore Tie2 activation to allow for enhancement of endothelial function and stabilization of blood vessels.2 Razuprotafib is being investigated against diabetic vascular complications and acute respiratory distress syndrome (ARDS) in COVID-19.
Target Actions Organism AReceptor-type tyrosine-protein phosphatase beta inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0WAX4UT396
- CAS number
- 1008510-37-9
- InChI Key
- KWJDHELCGJFUHW-SFTDATJTSA-N
- InChI
- InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
- IUPAC Name
- N-{4-[(2S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-phenylpropanamido]-2-[2-(thiophen-2-yl)-1,3-thiazol-4-yl]ethyl]phenyl}sulfamic acid
- SMILES
- COC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(NS(O)(=O)=O)C=C1)C1=CSC(=N1)C1=CC=CS1
References
- General References
- External Links
- ChemSpider
- 59718647
- ChEMBL
- CHEMBL3931971
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Diabetic Macular Edema (DME) 1 2 Completed Treatment NPDR - Non Proliferative Diabetic Retinopathy 1 2 Completed Treatment Ocular Hypertension / Ocular Hypertension, Primary Open-angle Glaucoma (POAG) 1 2 Completed Treatment Retinal Vein Occlusion 1 2 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) / Respiratory Distress Syndrome, Acute (ARDS) 1 1 Completed Treatment Healthy Subjects (HS) 1 1 Completed Treatment Ocular Hypertension / Ocular Hypertension, Primary Open-angle Glaucoma (POAG) 1 1, 2 Completed Treatment Diabetic Macular Edema (DME) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00482 mg/mL ALOGPS logP 2.64 ALOGPS logP 1.65 ChemAxon logS -5.1 ALOGPS pKa (Strongest Acidic) -1.4 ChemAxon pKa (Strongest Basic) 1.22 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 146.72 Å2 ChemAxon Rotatable Bond Count 11 ChemAxon Refractivity 157.23 m3·mol-1 ChemAxon Polarizability 58.89 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transmembrane receptor protein tyrosine phosphatase activity
- Specific Function
- Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce deph...
- Gene Name
- PTPRB
- Uniprot ID
- P23467
- Uniprot Name
- Receptor-type tyrosine-protein phosphatase beta
- Molecular Weight
- 224299.74 Da
References
- Aerpio Pharmaceuticals: Razuprotafib (AKB-9778) Diabetic Nephropathy [Link]
Drug created at December 15, 2020 22:05 / Updated at February 21, 2021 18:55